Photocure ASA

Regulatory Filings • May 18, 2022

Blue Light Cystoscopy continues to make news at AUA 2022

Blue Light Cystoscopy continues to make news at AUA 2022

Press Release - Oslo, Norway, May 18, 2022: Photocure ASA (OSE: PHO), the

Bladder Cancer Company, announces the conclusion of a productive AUA 2022

Conference: the American Urological Association Annual Congress 2022, an in

-person event for the first time since 2019, was held May 13-16, 2022 in New

Orleans, LA, USA. Both the Photocure and Karl Storz exhibit booths provided

information to AUA attendees on the New Blue Light equipment, for which interest

was strong. During the program, a poster by Dr. Sia Daneshmand was presented on

restaging TURBTs in NMIBC* featuring Photocure's Cysview[®] product.

The American Urological Association (AUA) meeting is one of largest

international meetings in the urology calendar. The yearly event includes an

innovative, evidence-based, quality program for urologists and urologic health

care professionals worldwide.

The New Blue Light equipment from Karl Storz was prominently displayed on the

exhibition floor, as urologists visited both the Photocure and Karl Storz booths

to inquire about the New Blue Light System, the next generation equipment in

bladder cancer detection. The Karl Storz equipment is the only FDA approved

device for BLC with Cysview in the U.S. Physicians were able to get hands on

experience with the new system at the Karl Storz booth.

"We have been working closely with Karl Storz for several months to support a

successful launch of the New Blue Light system and were very pleased with the

interest expressed among uro-oncologists who visited our booth on the exhibition

floor. We were able to share some of the key features and benefits of The New

Blue Light and liaised with the Karl Storz team for firsthand demonstrations.

Given the positive feedback during AUA, we anticipate that several launch events

will support the education and practice needs for the urology community.

Additionally, Photocure prominently displayed the Flexible BLC system at its

booth. The positive feedback from uro-oncologists further reinforces the recent

surge in flexible blue light tower installations and how outpatient surveillance

with flexible BLC helps support the continuum of care for patients with bladder

cancer." said Geoff Coy, Vice President & General Manager North America.

This year's AUA program also once again featured NMIBC topics including Blue

Light Cystoscopy. A poster from Dr. Sia Daneshmand was presented entitled "Is a

Restaging TURBT** Necessary in Non-Muscle Invasive Bladder Cancer if the Initial

TURBT was Performed Using Blue Light?" This podium poster presentation

highlighted that patients who underwent BLC for their initial TURBT had more

benign pathology upon a restaging TURBT compared to WLC, though a restaging

TURBT is still advised. Dr. Sia Daneshmand, M.D., is Professor of Urology with

Clinical Scholar designation and serves as director of clinical research as well

as the urologic oncology (SUO) fellowship director at the University of Southern

California (USC) in Los Angeles.

Read the abstract here:

https://www.eventscribe.net/2022/AUA2022/fsPopup.asp?Mode=presInfo&PresentationID

\=1051890

*NMIBC: Non-muscle invasive bladder cancer

**TURBT: Transurethral resection of bladder tumor

Note to editors:

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA

About Bladder Cancer

Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most

common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],

573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high

recurrence rate with up to 61% in year one and up to 78% over five years.[2]

Bladder cancer has the highest lifetime treatment costs per patient of all

cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients

have to undergo multiple cystoscopies due to the high risk of recurrence. There

is an urgent need to improve both the diagnosis and the management of bladder

cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer

(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of

invasion in the bladder wall. NMIBC remains in the inner layer of cells lining

the bladder. These cancers are the most common (75%) of all BC cases and include

the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has

grown into deeper layers of the bladder wall. These cancers, including subtypes

T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.

Available at: https://gco.iarc.fr/today, accessed [January 2022].

[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

[3] Sievert KD et al. World J Urol 2009;27:295-300

[4] Bladder Cancer. American Cancer

Society. https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the

bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC

with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves

the detection of tumors and leads to more complete resection, fewer residual

tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in

all other markets. Photocure is commercializing Cysview/Hexvix directly in the

U.S. and Europe and has strategic partnerships for the commercialization of

Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to

https://photocure.com/partners/our-partners for further information on our

commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Email: ds@photocure.com

Erik Dahl

CFO

Photocure ASA

Tel: +4745055000

Email: ed@photocure.com

David Moskowitz

Vice President, Investor Relations

Photocure ASA

Tel: +1 202 280 0888

Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no